microtubule associated protein RP/EB family member 3Genealiases: EB3 · EBF3 · EBF3-S · RP3
Q-omics provides the consensus-scored MAPRE3 profile across patient tissues and cancer cell-line models. MAPRE3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MAPRE3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MAPRE3 protein abundance shows 44,690 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, COAD, and GBM as cancer lineages where MAPRE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPRE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPRE3 survival associations across molecular data types. MAPRE3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPRE3 RNA expression–survival associations across cancer types. High MAPRE3 expression shows unfavorable associations in MESO, KIRP and THYM, but favorable associations in LUAD, SKCM and LUSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MAPRE3 RNA expression.
This table summarizes MAPRE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 11. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAPRE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPRE3 shows lower tumor expression in COAD, THCA, LUAD, UCEC and BRCA and higher tumor expression in CHOL. The COAD box plot shows higher MAPRE3 RNA expression in normal versus tumor tissue (log2 FC = −0.700, t-test p < 0.001).
This table shows molecular features associated with MAPRE3 in patient tissues and cancer cell lines. In patient samples, MAPRE3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPRE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
